-
货号
KDH28805
-
描述
PRINCIPLE OF THE ASSAY This assay employs the quantitative indirect enzyme immunoassay technique. Recombinant Human IL17A has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Secukinumab present is bound by the immobilized protein. After washing away any unbound substances, abiotin-labeled Mouse Anti-Human IgG antibody is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Secukinumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
-
应用
Used for the quantitative determination of Secukinumab concentration in serum and plasma. -
检测方法
Colorimetric -
样本类型
Plasma, Serum -
实验类型
Quantitative -
检测范围
937.5 - 15,000 ng/mL -
灵敏度
715.94 ng/mL. -
精准度
Intra-Assay Precision (Precision within an assay): <10%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <15%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision. -
回收率
80-120% -
运输
2-8 ℃ -
稳定性和存储
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃. -
别名
AIN457, CAS: 1229022-83-6
-
背景
Secukinumab (Cosentyx) is a fully human IgG1/κ-class monoclonal antibody (mAb) composed of 215 light chain amino acids and 457 heavy chain amino acids. It was discovered and developed by Novartis with the developmental name AIN457, for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. It is produced in Chinese Hamster Ovary (CHO) cells using recombinant DNA technology.
